|
 |
|
|||||||
|
|||||||||
Copyright © ERS Journals Ltd 2000
Original Articles |
Endothelin mediates pulmonary vascular remodelling in a canine model of chronic embolic pulmonary hypertension
It is well known that endothelin (ET)-1 mediates vascular remodelling in various kinds of clinical and experimental pulmonary hypertension. The aim of this study was to investigate whether ET-1 is associated with the development of pulmonary vascular remodelling in a canine model of chronic embolic pulmonary hypertension. Pulmonary hypertension was induced in 10 mongrel dogs by repeated embolization with ceramic beads. In five of the dogs, bosentan, a nonselective ET receptor antagonist, was administered throughout the study. Haemodynamic measurements and plasma ET-1 assays were performed every 2 months. Eight months after initial embolization, computer-assisted morphometry and immunohistochemistry were performed on the lung tissue including that from three control dogs. Pulmonary arterial pressure and pulmonary vascular resistance were increased in all embolized dogs, compared to baseline. In nontreated embolized dogs, plasma ET-1 concentration and pulmonary arterial wall thickness were increased compared to control animals, and ET-1 immunoreactivity was detected in thickened pulmonary arteries. In bosentan treated dogs, pulmonary arterial walls were not significantly thickened. Pulmonary vascular remodelling, associated with elevated plasma endothelin-1 levels and positive endothelin-1 immunoreactivity in lung tissue is attenuated by the endothelin receptor antagonist, bosentan. These findings suggest that endothelin mediates pulmonary vascular remodelling in a canine model of chronic embolic pulmonary hypertension.
This article has been cited by other articles:
|
|
 |
|
  I. M. Lang Managing chronic thromboembolic pulmonary hypertension: pharmacological treatment options Eur. Respir. Rev., March 1, 2009; 18(111): 24 - 28. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 C. F. Opitz, R. Ewert, W. Kirch, and D. Pittrow Inhibition of endothelin receptors in the treatment of pulmonary arterial hypertension: does selectivity matter? Eur. Heart J., August 2, 2008; 29(16): 1936 - 1948. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 G. Yung Lung Transplantation and Pulmonary Hypertension Seminars in Cardiothoracic and Vascular Anesthesia, June 1, 2007; 11(2): 149 - 156. [Abstract] [PDF]
|
|
|
|
 |
|
 D J Fox and R S Khattar Pulmonary arterial hypertension: classification, diagnosis and contemporary management Postgrad. Med. J., November 1, 2006; 82(973): 717 - 722. [Full Text] [PDF]
|
|
|
|
 |
|
 N. Galie and N. H. S. Kim Pulmonary Microvascular Disease in Chronic Thromboembolic Pulmonary Hypertension Proceedings of the ATS, September 1, 2006; 3(7): 571 - 576. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
P. Bresser, J. Pepke-Zaba, X. Jais, M. Humbert, and M. M. Hoeper Medical Therapies for Chronic Thromboembolic Pulmonary Hypertension: An Evolving Treatment Paradigm Proceedings of the ATS, September 1, 2006; 3(7): 594 - 600. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
A. Peacock, G. Simonneau, and L. Rubin Controversies, Uncertainties and Future Research on the Treatment of Chronic Thromboembolic Pulmonary Hypertension Proceedings of the ATS, September 1, 2006; 3(7): 608 - 614. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 R. J. Hughes, X. Jais, D. Bonderman, J. Suntharalingam, M. Humbert, I. Lang, G. Simonneau, and J. Pepke-Zaba The efficacy of bosentan in inoperable chronic thromboembolic pulmonary hypertension: a 1-year follow-up study Eur. Respir. J., July 1, 2006; 28(1): 138 - 143. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 M. M. Hoeper, E. Mayer, G. Simonneau, and L. J. Rubin Chronic Thromboembolic Pulmonary Hypertension Circulation, April 25, 2006; 113(16): 2011 - 2020. [Full Text] [PDF]
|
|
|
|
 |
|
 L. J. Rubin and D. B. Badesch Evaluation and Management of the Patient with Pulmonary Arterial Hypertension Ann Intern Med, August 16, 2005; 143(4): 282 - 292. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 D. B. Badesch, S. H. Abman, G. S. Ahearn, R. J. Barst, D. C. McCrory, G. Simonneau, and V. V. McLaughlin Medical Therapy For Pulmonary Arterial Hypertension: ACCP Evidence-Based Clinical Practice Guidelines Chest, July 1, 2004; 126(1_suppl): 35S - 62S. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 R. N. Channick, O. Sitbon, R. J. Barst, A. Manes, and L. J. Rubin Endothelin receptor antagonists in pulmonary arterial hypertension J. Am. Coll. Cardiol., June 16, 2004; 43(12_Suppl_S): 62S - 67S. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
P. Bresser, P.F. Fedullo, W.R. Auger, R.N. Channick, I.M. Robbins, K.M. Kerr, S.W. Jamieson, and L.J. Rubin Continuous intravenous epoprostenol for chronic thromboembolic pulmonary hypertension Eur. Respir. J., April 1, 2004; 23(4): 595 - 600. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 J.-H. LEE, Y.-G. CHUN, I.-C. LEE, R. M. TUDER, S.-B. HONG, T.-S. SHIM, C.-M. LIM, Y. KOH, W.-S. KIM, D.-S. KIM, et al. Pathogenic Role of Endothelin 1 in Hemodynamic Dysfunction in Experimental Acute Pulmonary Thromboembolism Am. J. Respir. Crit. Care Med., October 1, 2001; 164(7): 1282 - 1287. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
S. Eddahibi and S. Adnot Endothelins and pulmonary hypertension, what directions for the near future? Eur. Respir. J., July 1, 2001; 18(1): 1 - 4. [Full Text] [PDF]
|
|
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |